IL2 and systemic lupus erythematosus: By inducing immune tolerance [30], Ld-IL2 therapy is emerging as a new approach to treat autoimmune and inflammatory diseases and has shown safety and promising efficacy in a broad range of conditions including GVHD [38], SLE [37,46,47,57,58], type 1 diabetes [41,42,59] and hepatitis C virus (HCV) induced vasculitis [40].